Dyne Therapeutics (NASDAQ:DYN) Insider Sells $28,715.04 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Douglas Kerr sold 1,564 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total value of $28,715.04. Following the completion of the sale, the insider directly owned 170,042 shares of the company’s stock, valued at $3,121,971.12. This trade represents a 0.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dyne Therapeutics Stock Down 0.9%

Dyne Therapeutics stock traded down $0.16 during mid-day trading on Thursday, reaching $18.28. The stock had a trading volume of 913,113 shares, compared to its average volume of 2,034,526. The company has a debt-to-equity ratio of 0.17, a quick ratio of 22.25 and a current ratio of 19.92. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The stock’s 50-day simple moving average is $18.22 and its 200-day simple moving average is $18.63. The firm has a market capitalization of $3.02 billion, a PE ratio of -5.68 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period last year, the firm posted ($1.05) earnings per share. On average, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -2.97 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on DYN. JPMorgan Chase & Co. reduced their price objective on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th. Sanford C. Bernstein raised their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Wall Street Zen lowered Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 2nd. Finally, Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.21.

Institutional Trading of Dyne Therapeutics

Hedge funds have recently bought and sold shares of the business. Hilton Head Capital Partners LLC bought a new stake in Dyne Therapeutics during the first quarter worth $26,000. Chung Wu Investment Group LLC bought a new stake in Dyne Therapeutics during the third quarter worth $30,000. Strs Ohio bought a new stake in Dyne Therapeutics during the fourth quarter worth $51,000. Aster Capital Management DIFC Ltd bought a new stake in Dyne Therapeutics during the fourth quarter worth $84,000. Finally, Steward Partners Investment Advisory LLC lifted its holdings in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after acquiring an additional 2,465 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Lifesci Capital raised its Q2, Q3 and Q4 2026 EPS estimates for Dyne Therapeutics, suggesting slightly better expected performance in the near term. Dyne Therapeutics analyst estimate updates
• Positive Sentiment: HC Wainwright also lifted its Q2, Q3 and FY2026 EPS estimates and maintained a Buy rating with a $50 price target, reinforcing a bullish longer-term outlook. Dyne Therapeutics analyst estimate updates
• Neutral Sentiment: Dyne Therapeutics said management will participate in upcoming investor conferences, which keeps the company visible to the market but does not by itself change fundamentals. Dyne Therapeutics to Participate in Upcoming Investor Conferences
• Negative Sentiment: Not all longer-dated estimates improved: HC Wainwright cut its FY2027, FY2028, FY2029 and FY2030 EPS forecasts, which may temper enthusiasm around the company’s longer-term profitability outlook. Dyne Therapeutics analyst estimate updates

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.